Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA)
2024-512436-29-00Phase 4Authorised
- Sponsor
- Fundación Epic
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ticagrelor, prasugrel and clopidogrel in acute coronary syndrome (ACS) and cardiac morbidity, sponsored by Fundación Epic. Primary endpoint: Net Adverse Cardiac Events (NACE). Planned start Apr 2024; status: authorised.
02
Drugs
ticagrelorprasugrelclopidogrel
03
Conditions
acute coronary syndrome (ACS)cardiac morbidity
Beyond the preview
Go deeper on 2024-512436-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512436-29-00.